Clinical Ink acquires Digital Artefacts 

Clinical Ink, a clinical trial data and technology company, has acquired Digital Artefacts, a digital endpoint-based technology company.  

“The addition of Digital Artefacts now allows us to drive situational awareness because context matters. Data derived from Digital Artefacts can now increase the richness of our partners’ study data through the convergence of passive and active digital assessments. Their wearables and sensors acumen provides instrumented data collection that complements our existing products and solutions,” said Clinical Ink CEO Ed Seguine.  

The combination of Clinical Ink and Digital Artefacts will provide benefits including: 

  • Scientifically validated neurocognitive assessment and research tools (50+ modular, self-administered assessments)
  • Combination of standardised eCOA scales/assessments with novel digital endpoints to produce quantitative patient outcomes 
  • Trial specific remote active and passive behavioral assessment, including wearable and sensor data 
  • Precision Real-World Data and insights across complex therapeutic areas for which cognition is an endpoint
  • Expertise in creating clinically relevant novel digital endpoint data collection methodologies including voice, movement, behavior, mood, and other real-world measurements 
  • Scaled delivery capabilities in logistics, helpdesk, project management, and device acquisition/support for DCTs 

These capabilities reinforce Clinical Ink’s reputation as a trusted, global partner in digital source data capture (DDC) and eCOA, furthering the company’s therapeutic-area-specific approach to study design and data certainty from source to submission. 

“Our digital endpoint solutions, combined with strong data science, provide expertise that has been foundational with industry recognised partners and top pharma,” noted Joan Severson, Co-founder, President, and General Manager of Digital Artefacts. “We are very excited to join Clinical Ink and enhance the seamless data collection, cognitive and behavioral assessments, and quantitative outcomes for even the most complex studies.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free